CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 60 enrolled
Drug / intervention
temozolomidedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00619112
NCT00619112Phase 2Completed
CompareCT.gov

Phase II Study of 7 Days On/7 Days Off Temozolomide in Patients With High-Grade Glioma

University of California, San Francisco·interventional·Posted Feb 20, 2008·Updated Jan 31, 2018

In Brief

A Phase 2 clinical trial evaluating temozolomide for Recurrent Central Nervous System Neoplasm. Completed, enrolled 60 participants across 1 site.

Detailed Summary

RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well temozolomide works in treating patients with recurrent high-grade glioma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Central Nervous System Neoplasm
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 20, 2008
Enrollment StartOct 1, 2007
Primary CompletionDec 1, 2011
Study CompletionSep 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 18.4 years ago

Interventions

temozolomidedrug

single arm study